These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26727844)

  • 1. [U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal anti-inflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective].
    Rosen E; Tsesis I; Vered M
    Refuat Hapeh Vehashinayim (1993); 2015 Oct; 32(4):6-10, 25. PubMed ID: 26727844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hot topics in pain management: using NSAIDs safely.
    D'Arcy Y
    Nursing; 2006 Feb; 36(2):22-3. PubMed ID: 16462239
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
    Roumie CL; Choma NN; Kaltenbach L; Mitchel EF; Arbogast PG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1053-63. PubMed ID: 19637402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C
    BMJ; 2005 Jun; 330(7504):1366. PubMed ID: 15947398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.
    Abraham NS; El-Serag HB; Hartman C; Richardson P; Deswal A
    Aliment Pharmacol Ther; 2007 Apr; 25(8):913-24. PubMed ID: 17402995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 9. Pain drugs and heart attack. What's your risk?
    Mayo Clin Health Lett; 2013 Apr; 31(4):6. PubMed ID: 24696897
    [No Abstract]   [Full Text] [Related]  

  • 10. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective cyclooxygenase 2 inhibitors and cardiovascular events.
    Solomon DH
    Arthritis Rheum; 2005 Jul; 52(7):1968-78. PubMed ID: 15986365
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 13. Do NSAIDs actually protect against myocardial infarction and death?
    van Beers EJ; de Groot JR; Tijssen JG
    Clin Pharmacol Ther; 2009 Dec; 86(6):601-2; author reply 602-4. PubMed ID: 19865082
    [No Abstract]   [Full Text] [Related]  

  • 14. No obvious extra cardiovascular risk associated with low-dose NSAIDs.
    Moore N
    Clin Pharmacol Ther; 2009 Dec; 86(6):600-1; author reply 602-4. PubMed ID: 19421187
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pain medications. Options may be changing.
    Mayo Clin Health Lett; 2005 May; 23(5):4-5. PubMed ID: 15986506
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events.
    Cheng JW
    Ann Pharmacother; 2006 Oct; 40(10):1785-96. PubMed ID: 16985093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.